$BIXT Bioxytran Peer-Reviewed Journal in “Vaccin
Post# of 44278
(Total Views: 81)
Posted On: 07/21/2023 8:59:27 AM
$BIXT Bioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 Mutations Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)
Complete elimination of most symptoms by day 7
Galectin antagonist acts as an entry inhibitor for use in treatment of COVID-19
BOSTON, MASSACHUSETTS, June 27, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that the journal “Vaccines” released a peer-reviewed article, “An Oral Galectin Inhibitor in COVID-19 – A Phase 2 Randomized Controlled Trial”, which contains top-line safety and efficacy results of the Company’s randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19. During the 7 days of treatment, an orally administered Galectin Antagonist in the form of a chewable tablet was administered. The endpoint was a statistically significant reduction in viral load measured by the number of patients reaching a below threshold PCR value (Ct value ≥ 29) by day 7. Additionally, most of the symptoms completely disappeared in the group receiving the drug whereas the placebo group had 41.18% of patients that continued to experience chills, 29.41% that had a feverish sensation, and 35.29% that had a cough on day 7. The trial met its endpoint with a 100% response rate by day 7 versus 6% in placebo, which was statistically significant (p-value =.001).
https://finance.yahoo.com/news/bioxytran-peer...00200.html
Complete elimination of most symptoms by day 7
Galectin antagonist acts as an entry inhibitor for use in treatment of COVID-19
BOSTON, MASSACHUSETTS, June 27, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that the journal “Vaccines” released a peer-reviewed article, “An Oral Galectin Inhibitor in COVID-19 – A Phase 2 Randomized Controlled Trial”, which contains top-line safety and efficacy results of the Company’s randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19. During the 7 days of treatment, an orally administered Galectin Antagonist in the form of a chewable tablet was administered. The endpoint was a statistically significant reduction in viral load measured by the number of patients reaching a below threshold PCR value (Ct value ≥ 29) by day 7. Additionally, most of the symptoms completely disappeared in the group receiving the drug whereas the placebo group had 41.18% of patients that continued to experience chills, 29.41% that had a feverish sensation, and 35.29% that had a cough on day 7. The trial met its endpoint with a 100% response rate by day 7 versus 6% in placebo, which was statistically significant (p-value =.001).
https://finance.yahoo.com/news/bioxytran-peer...00200.html
(0)
(0)